该公司在监管审批方面也取得了重大进展，获得了22个MDR CE标志中的14个，并预计其最大的美国产品Artegraft将在2025年6月前在欧洲获得批准。 LeMaitre Vascular正积极寻求收购，特别是在开放性血管手术领域和相邻市场如心脏手术和血管内治疗领域。公司销售团队的 ...

The company also exhibited significant progress in its regulatory approvals, receiving 14 out of 22 MDR CE Marks, and expects approval for Artegraft, its largest American product, in Europe by June ...

The company also exhibited significant progress in its regulatory approvals, receiving 14 out of 22 MDR CE Marks, and expects approval for Artegraft, its largest American product, in Europe by ...

鉴于此，公司已开始寻找新的CFO。 LeMaitre Vascular在监管方面取得重大进展，已获得22个MDR CE认证中的14个。公司预计其最大的美国产品Artegraft将在2025年6月前在欧洲获得批准。尽管由于制造效率和成本上升可能导致第三季度毛利率略有下降，但公司对其增长战略仍 ...

Bovine Patches Growth: 12% increase. Shunts Growth ... A: George LeMaitre, CEO, explained that the expansion is due to the territories being too large, especially after the Artegraft acquisition in ...